Trial Profile
A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Glesatinib (Primary) ; Mocetinostat (Primary) ; Nivolumab (Primary) ; Sitravatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Mirati Therapeutics
- 24 Feb 2023 Primary endpoint (Objective response rate (ORR)) has not been met, as per results published in the Journal of Thoracic Oncology.
- 24 Feb 2023 Results (n=156) assessing efficacy and safety of sitravatinib with nivolumab in patients with non-squamous non-small cell lung cancer, published in the Journal of Thoracic Oncology.
- 15 Apr 2022 Status changed from active, no longer recruiting to completed.